Impact of Mutations at Residue I223 of the Neuraminidase Protein on the Resistance Profile, Replication Level, and Virulence of the 2009 Pandemic Influenza Virus

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2011 Dec 29

PMID 22203589

Citations 34

Authors

Andres Pizzorno

Yacine Abed

Xavier Bouhy

Edith Beaulieu

Corey Mallett

Rupert Russell

Guy Boivin

Affiliations

Soon will be listed here.

Abstract

Amino acid substitutions at residue I223 of the neuraminidase (NA) protein have been identified in 2009 pandemic influenza (pH1N1) variants with altered susceptibilities to NA inhibitors (NAIs). We used reverse genetics and site-directed mutagenesis to generate the recombinant A/Québec/144147/09 pH1N1 wild-type virus (WT) and five (I223R, I223V, H275Y, I223V-H275Y, and I223R-H275Y) NA mutants. A fluorimetry-based assay was used to determine 50% inhibitory concentrations (IC(50)s) of oseltamivir, zanamivir, and peramivir. Replicative capacity was analyzed by viral yield assays in ST6GalI-MDCK cells. Infectivity and transmission of the WT, H275Y, and I223V-H275Y recombinant viruses were evaluated in ferrets. As expected, the H275Y mutation conferred resistance to oseltamivir (982-fold) and peramivir (661-fold) compared to the drug-susceptible recombinant WT. The single I223R mutant was associated with reduced susceptibility to oseltamivir (53-fold), zanamivir (7-fold) and peramivir (10-fold), whereas the I223V virus had reduced susceptibility to oseltamivir (6-fold) only. Interestingly, enhanced levels of resistance to oseltamivir and peramivir and reduced susceptibility to zanamivir (1,647-, 17,347-, and 16-fold increases in IC(50)s, respectively) were observed for the I223R-H275Y recombinant, while the I223V-H275Y mutant exhibited 1,733-, 2,707-, and 2-fold increases in respective IC(50)s. The I223R and I223V changes were associated with equivalent or higher viral titers in vitro compared to the recombinant WT. Infectivity and transmissibility in ferrets were comparable between the recombinant WT and the H275Y or I223V-H275Y recombinants. In conclusion, amino acid changes at residue I223 may alter the NAI susceptibilities of pH1N1 variants without compromising fitness. Consequently, I223R and I223V mutations, alone or with H275Y, need to be thoroughly monitored.

Citing Articles

Molecular dynamics study on the effect of the N1 neuraminidase double mutant G147R/H274Y on oseltamivir sensitivity.

Nurrohman A, Suwito H, Puspaningsih N, Haq K RSC Adv. 2024; 14(52):39017-39026.

PMID: 39659606 PMC: 11629752. DOI: 10.1039/d4ra07713j.

Influenza neuraminidase mutations and resistance to neuraminidase inhibitors.

Xu J, Luo Q, Huang Y, Li J, Ye W, Yan R Emerg Microbes Infect. 2024; 13(1):2429627.

PMID: 39530458 PMC: 11600549. DOI: 10.1080/22221751.2024.2429627.

Increase of Synergistic Secondary Antiviral Mutations in the Evolution of A(H1N1)pdm09 Influenza Virus Neuraminidases.

Duwe S, Milde J, Heider A, Wedde M, Schweiger B, Durrwald R Viruses. 2024; 16(7).

PMID: 39066271 PMC: 11281601. DOI: 10.3390/v16071109.

Low prevalence of influenza A strains with resistance markers in Brazil during 2017-2019 seasons.

Sousa T, Martins J, Miranda M, Garcia C, Resende P, Santos C Front Public Health. 2022; 10:944277.

PMID: 36187691 PMC: 9516282. DOI: 10.3389/fpubh.2022.944277.

Antivirals Targeting the Surface Glycoproteins of Influenza Virus: Mechanisms of Action and Resistance.

Bai Y, Jones J, Wong S, Zanin M Viruses. 2021; 13(4).

PMID: 33917376 PMC: 8067422. DOI: 10.3390/v13040624.

References

Mishin V, Hayden F, Gubareva L . Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother. 2005; 49(11):4515-20. PMC: 1280118. DOI: 10.1128/AAC.49.11.4515-4520.2005. View

Hamelin M, Baz M, Abed Y, Couture C, Joubert P, Beaulieu E . Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog. 2010; 6(7):e1001015. PMC: 2908621. DOI: 10.1371/journal.ppat.1001015. View

Hamelin M, Baz M, Bouhy X, Beaulieu E, Dube K, Mallett C . Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets. Antivir Ther. 2011; 16(5):775-9. DOI: 10.3851/IMP1794. View

Davies B . Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. J Antimicrob Chemother. 2010; 65 Suppl 2:ii5-ii10. PMC: 2835511. DOI: 10.1093/jac/dkq015. View

Potier M, Mameli L, Belisle M, DALLAIRE L, Melancon S . Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal Biochem. 1979; 94(2):287-96. DOI: 10.1016/0003-2697(79)90362-2. View

Baz M, Abed Y, McDonald J, Boivin G . Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis. 2006; 43(12):1555-61. DOI: 10.1086/508777. View

Baz M, Abed Y, Papenburg J, Bouhy X, Hamelin M, Boivin G . Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis. N Engl J Med. 2009; 361(23):2296-7. DOI: 10.1056/NEJMc0910060. View

Shelton M, Lovern M, Ng-Cashin J, Jones L, Gould E, Gauvin J . Zanamivir pharmacokinetics and pulmonary penetration into epithelial lining fluid following intravenous or oral inhaled administration to healthy adult subjects. Antimicrob Agents Chemother. 2011; 55(11):5178-84. PMC: 3195002. DOI: 10.1128/AAC.00703-11. View

Pizzorno A, Abed Y, Boivin G . Influenza drug resistance. Semin Respir Crit Care Med. 2011; 32(4):409-22. DOI: 10.1055/s-0031-1283281. View

10.

Yen H, Hoffmann E, Taylor G, Scholtissek C, Monto A, Webster R . Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol. 2006; 80(17):8787-95. PMC: 1563878. DOI: 10.1128/JVI.00477-06. View

11.

Hatakeyama S, Sakai-Tagawa Y, Kiso M, Goto H, Kawakami C, Mitamura K . Enhanced expression of an alpha2,6-linked sialic acid on MDCK cells improves isolation of human influenza viruses and evaluation of their sensitivity to a neuraminidase inhibitor. J Clin Microbiol. 2005; 43(8):4139-46. PMC: 1233980. DOI: 10.1128/JCM.43.8.4139-4146.2005. View

12.

Nguyen H, Fry A, Loveless P, Klimov A, Gubareva L . Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis. 2010; 51(8):983-4. DOI: 10.1086/656439. View

13.

Hurt A, Holien J, Barr I . In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses. Antimicrob Agents Chemother. 2009; 53(10):4433-40. PMC: 2764219. DOI: 10.1128/AAC.00334-09. View

14.

Pizzorno A, Bouhy X, Abed Y, Boivin G . Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors. J Infect Dis. 2010; 203(1):25-31. PMC: 3086433. DOI: 10.1093/infdis/jiq010. View

15.

Maines T, Jayaraman A, Belser J, Wadford D, Pappas C, Zeng H . Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science. 2009; 325(5939):484-7. PMC: 2953552. DOI: 10.1126/science.1177238. View

16.

Liu Q, Wang S, Ma G, Pu J, Forbes N, Brown E . Improved and simplified recombineering approach for influenza virus reverse genetics. J Mol Genet Med. 2010; 3(2):225-31. PMC: 2805844. DOI: 10.4172/1747-0862.1000039. View

17.

Memoli M, Hrabal R, Hassantoufighi A, Eichelberger M, Taubenberger J . Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis. 2010; 50(9):1252-5. PMC: 2946636. DOI: 10.1086/651605. View

18.

Colman P, Hoyne P, Lawrence M . Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol. 1993; 67(6):2972-80. PMC: 237633. DOI: 10.1128/JVI.67.6.2972-2980.1993. View

19.

Herlocher M, Truscon R, Elias S, Yen H, Roberts N, Ohmit S . Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis. 2004; 190(9):1627-30. DOI: 10.1086/424572. View

20.

Abed Y, Baz M, Boivin G . Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther. 2007; 11(8):971-6. View